X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs AUROBINDO PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS AUROBINDO PHARMA IPCA LABS/
AUROBINDO PHARMA
 
P/E (TTM) x 29.5 19.5 151.2% View Chart
P/BV x 4.4 3.9 113.1% View Chart
Dividend Yield % 0.1 0.3 33.1%  

Financials

 IPCA LABS   AUROBINDO PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
AUROBINDO PHARMA
Mar-18
IPCA LABS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs695809 86.0%   
Low Rs400504 79.4%   
Sales per share (Unadj.) Rs260.2281.1 92.6%  
Earnings per share (Unadj.) Rs19.041.4 45.9%  
Cash flow per share (Unadj.) Rs33.150.9 65.0%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %0.20.4 47.9%  
Book value per share (Unadj.) Rs213.0199.4 106.9%  
Shares outstanding (eoy) m126.20585.88 21.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.12.3 90.1%   
Avg P/E ratio x28.915.9 181.9%  
P/CF ratio (eoy) x16.612.9 128.4%  
Price / Book Value ratio x2.63.3 78.1%  
Dividend payout %5.36.0 87.2%   
Avg Mkt Cap Rs m69,120384,630 18.0%   
No. of employees `00013.317.3 76.5%   
Total wages/salary Rs m7,35921,308 34.5%   
Avg. sales/employee Rs Th2,477.49,500.7 26.1%   
Avg. wages/employee Rs Th555.21,229.4 45.2%   
Avg. net profit/employee Rs Th180.61,397.9 12.9%   
INCOME DATA
Net Sales Rs m32,836164,666 19.9%  
Other income Rs m4181,020 41.0%   
Total revenues Rs m33,254165,686 20.1%   
Gross profit Rs m4,50537,718 11.9%  
Depreciation Rs m1,7775,580 31.9%   
Interest Rs m240777 30.9%   
Profit before tax Rs m2,90532,380 9.0%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5118,183 6.2%   
Profit after tax Rs m2,39424,229 9.9%  
Gross profit margin %13.722.9 59.9%  
Effective tax rate %17.625.3 69.6%   
Net profit margin %7.314.7 49.6%  
BALANCE SHEET DATA
Current assets Rs m19,455121,878 16.0%   
Current liabilities Rs m10,07686,806 11.6%   
Net working cap to sales %28.621.3 134.1%  
Current ratio x1.91.4 137.5%  
Inventory Days Days98130 75.4%  
Debtors Days Days6768 97.9%  
Net fixed assets Rs m20,26081,037 25.0%   
Share capital Rs m252586 43.1%   
"Free" reserves Rs m26,633116,218 22.9%   
Net worth Rs m26,886116,804 23.0%   
Long term debt Rs m2,3404,512 51.9%   
Total assets Rs m41,173211,052 19.5%  
Interest coverage x13.142.7 30.7%   
Debt to equity ratio x0.10 225.3%  
Sales to assets ratio x0.80.8 102.2%   
Return on assets %6.411.8 54.0%  
Return on equity %8.920.7 42.9%  
Return on capital %10.827.4 39.3%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64280,727 19.4%   
Fx outflow Rs m4,88434,700 14.1%   
Net fx Rs m10,75946,027 23.4%   
CASH FLOW
From Operations Rs m3,41119,548 17.5%  
From Investments Rs m-1,354-19,570 6.9%  
From Financial Activity Rs m-1,3048,642 -15.1%  
Net Cashflow Rs m7538,922 8.4%  

Share Holding

Indian Promoters % 45.9 54.1 84.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 8.0 143.4%  
FIIs % 25.3 27.7 91.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.2 170.6%  
Shareholders   36,892 69,601 53.0%  
Pledged promoter(s) holding % 2.1 8.6 25.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  STERLING BIOTECH  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Mar 22, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS